|
GSK PLC on Tuesday said its respiratory syncytial virus vaccine Arexvy has been accepted for review by China’s Center for Drug Evaluation for adults aged 60 and over. The London-based pharmaceuticals company said the review is regarding the prevention of lower respiratory tract disease caused by RSV. A regulatory decision is expected in 2027. GSK said: ‘If approved, Arexvy will be the first vaccine available to this population in China to help protect against the potentially serious consequences of RSV disease.’ The regulatory submission is based on the vaccine’s ‘robust’ data package, the company said, including positive results from a phase 3 trial evaluating the safety and immunogenicity of the vaccine in adults aged 60 and older. Citing a 2024 report, GSK said that RSV is estimated to affect over six million adults aged 60 years and over in China per year, leading to over 350,000 RSV-related hospitalisations. GSK shares rose 1.3% to 2,186.00 pence each on Tuesday morning in London. Copyright 2026 Alliance News Ltd. All Rights Reserved.
|
